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ABSTRACT
Recently, insulin-like growth factor binding proteins
(IGFBPs) have been found to be primary mediators
of the anti-proliferative actions of the nuclear hor-
mone 1a,25-dihydroxyvitamin D3 [1a,25(OH)2D3],
but dependent on cellular context IGFBPs can also
have a mitogenic effect. In this study, we performed
expression profiling of all six human IGFBP genes
in prostate and bone cancer cells and demonstrated
that IGFBP1, 3 and 5 are primary 1a,25(OH)2D3 target
genes. In silico screening of the 174 kb of genomic
sequence surrounding all six IGFBP genes identified
15 candidate vitamin D response elements (VDREs)
close to or in IGFBP1, 2, 3 and 5 but not in the IGFBP4
and 6 genes. The putative VDREs were evaluated in
vitro by gelshift assays and in living cells by reporter
gene and chromatin immuno-precipitation (ChIP)
assays. Of these 10 VDREs appear to be functional.
ChIP assays demonstrated for each of these an
individual, stimulation time-dependent association
profile not only with the vitamin D receptor, but also
with first heterodimeric partner the retinoid X recep-
tor, other regulatory complex components and phos-
phorylatedRNApolymeraseII.SomeoftheVDREsare
located distantly from the transcription start sites of
IGFBP1, 3 and 5, but all 10 VDREs seem to contribute
totheregulationofthegenesby1a,25(OH)2D3.Incon-
clusion, IGFBP1, 3 and 5 are primary 1a,25(OH)2D3
target genes that in intact cells are each under the
control of multiple VDREs.
INTRODUCTION
The biologically most active vitamin D metabolite, 1a,25-
dihydroxyvitamin D3 [1a,25(OH)2D3], is essential for mineral
homeostasis and skeletal integrity (1). However, it also has
important roles in the control of the growth and differentiation
in normal tissues and malignant cells derived from prostate,
breast and bone (2). 1a,25(OH)2D3 mainly acts as a nuclear
hormone and mediates its genomic effects via the nuclear
receptor vitamin D receptor (VDR) (3). The anti-
proliferative effects of 1a,25(OH)2D3 include induction of
aG 1/G0 cell cycle arrest and stimulation of apoptosis,
which are mediated by the up-regulation of tumor suppressors,
such as the cyclin-dependent kinase inhibitory proteins
p21 and p27 (4), and the down-regulation of oncogene pro-
ducts including Bcl-2 (5) and Myc (6). Mitogens, such as the
insulin-like growth factors (IGFs), have also been reported to
be down-regulated by 1a,25(OH)2D3 (7). In addition, also the
up-regulation of factors which control the actions of mitogens,
such as IGF binding proteins (IGFBPs), have important anti-
cancer effects (8). Unfortunately, many of the genes involved
in these processes, such as the p27 and bcl-2, are secondary
1a,25(OH)2D3 targets (9). However, the IGFBP3 gene was
shown to be a primary VDR target (10) and is therefore of
special interest for understanding the mechanisms of the cell-
regulatory actions of 1a,25(OH)2D3. IGFBP3 belongs to the
six-member IGFBP family that bind IGFs with high afﬁnity
and speciﬁcity (11). IGFBPs also mediate IGF-independent
actions, including inhibition of cell growth and induction of
apoptosis (12). Since gene families often encode products,
which have overlapping functions, we wondered if this was
also true at the level of responsiveness to a particular ligand.
Therefore, we focused in this study on the regulation of the
IGFBP gene family by 1a,25(OH)2D3.
An essential prerequisite for the direct modulation of tran-
scription by 1a,25(OH)2D3 is the location of at least one
activated VDR protein close to the transcription start site
(TSS) of the respective primary 1a,25(OH)2D3 target gene.
This is achieved through the speciﬁc binding of VDR to a vit-
amin D response element (VDRE) (13). In detail, the DNA-
binding domain of the VDR contacts the major groove of
a double-stranded hexameric DNA sequence with the optimal
RGKTCA (R ¼ Ao rG ,K¼ G or T) core binding sequence.
VDR binds as a dimer to DNA and in most cases the nuclear
receptor retinoid X receptor (RXR) is its heterodimeric partner
(13). Simple VDREs are therefore formed by two hexameric
core binding motifs in a direct repeat (DR) or everted repeat
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was found to be 3 and 4 nt (DR3 and DR4) (14,15) and that of
ER-type VDREs 7 to 9 nt (ER7, ER8 and ER9), respectively
(16,17). Although individual VDREs have been shown to be
able to induce transactivation on their own, the presence of
multiple VDREs in any given regulatory region will allow
a more ﬂexible and complex regulation of the respective
gene. Recently, we have shown that the primary 1a,
25(OH)2D3 target genes CYP24 (18) and cyclin C (19) each
contain four functional VDREs within the ﬁrst 10 kb of their
promoter region. In the promoter of the human IGFBP3 gene
only one DR3-type VDRE so far has been reported, which is
located  3.2 kb upstream of the TSS (10). However, this does
not exclude the presence of additional VDREs.
Binding of VDR to a VDRE is a central step in
1a,25(OH)2D3 signaling. In the absence of ligand, corepressor
proteins, such as SMRT, NCoR and Alien (20), link DNA-
bound VDR to enzymes with histone deacetylase activity that
cause chromatin condensation (21). This provides VDR with
intrinsic repressive properties comparable with both retinoic
acidand thyroid hormone receptors(20).Ligandbinding tothe
VDR causes a conformational change within its ligand-
binding domain that results in the replacement of corepressors
by coactivator proteins of the p160-family, such as SRC-1,
TIF2 and RAC3 (22). These coactivator proteins link ligand-
activated VDR to enzymes displaying histone acetyltrans-
ferase activity, that cause chromatin relaxation and thereby
reversing the action of unliganded VDR (23). In a subsequent
step, ligand-activated VDR changes rapidly from interacting
with p160-coactivators to those of the mediator complex, such
as TRAP220/DRIP205 (24). The mediator complex acts as
a bridge from activated VDR to the basal transcriptional
machinery (25). In this way ligand-activated VDR executes
two tasks, the modiﬁcation of chromatin and the regulation of
transcription.
In this study, we performed expression proﬁling of all six
human IGFBP gene family members in prostate and bone
cancer cells and demonstrated that the genes IGFBP1, 3
and 5 are primary 1a,25(OH)2D3 targets. In silico screening
of all IGFBP genes identiﬁed 15 candidate VDREs close to
IGFBP1, 2, 3 and 5, but none within IGFBP4 and 6. Of these
10 VDREs seem to be functional and chromatin immuno-
precipitation (ChIP) assays demonstrated that for each of
them an individual, ligand-stimulation time-dependent asso-
ciation proﬁle with VDR, RXR,SMRT, SRC-1, TRAP220and
phosphorylated RNA polymerase II (P-Pol II). Some of the
VDREs are located rather distantly from the TSS of the
IGFBP1, 3 and 5, but all 10 functional VDREs appear to
contribute to their regulation by 1a,25(OH)2D3.
MATERIALS AND METHODS
Cell culture
The human prostate cancer cell line PC-3 and the human
osteosarcoma cell line SaOS-2 were cultured in DMEM con-
taining 10% fetal bovine serum (FBS), while for the human
breast cancer cell line MCF-7, a-MEM supplemented with 5%
FBS was used. Both media also contained 2 mM L-glutamine,
0.1 mg/ml streptomycin and 100 U/ml penicillin and the cells
werekept ina humidiﬁed95% air/5% CO2incubator.FBS was
stripped of lipophilic compounds, such as endogenous
1a,25(OH)2D3, by stirring it with 5% activated charcoal
(Sigma–Aldrich, St Louis, MO) for 3 h at room temperature.
Charcoal was then removed by centrifugation and sterile ﬁl-
tration. Prior to mRNA or chromatin extraction, cells were
grown overnight in phenol red-free DMEM supplemented
with 5% charcoal-stripped FBS to reach a density of 50–
60% conﬂuency. Cells were treated then with solvent (ethanol,
0.1% ﬁnal concentration) or 10 nM 1a,25(OH)2D3 (kindly
provided by Dr Lise Binderup, LEO Pharma, Ballerup,
Denmark) for up to 24 h for RNA extractions and for up to
4 h for chromatin preparations.
RNA extraction and real-time quantitative PCR
Total RNA was extracted using the Mini RNA Isolation II kit
(Zymo Research, HiSS Diagnostics, Freiburg, Germany) and
cDNA synthesis was performed for 1 h at 37 C using 1 mgo f
total RNA as a template, 100 pmol oligodT18 primer and 40 U
RT (Fermentas, Vilnius, Lithuania). Real-time quantitative
PCR was performed in an IQ-cycler (BioRad, Hercules,
CA) using the dye SybrGreen I (Molecular Probes, Leiden,
The Netherlands). For each reaction, 1 U Hot Start Taq poly-
merase (Fermentas) and 3 mM MgCl2 were used and the PCR
cyclingconditions were: 45 cycles of30sat95 C,30 sat62 C
and 40 s at 72 C. The gene-speciﬁc primer pairs (and product
sizes) were as follows: IGFBP1 gene, forward 50-CACAGGA-
GACATCAGGAGAAG-30 and reverse 50-GAGCTTTGGAA-
GAGCAGAAATG-30 (507 bp); IGFBP2 gene, forward
50-GATGACCACTCAGAAGGAG-30 and reverse 50-CTGC-
TGCTCATTGTAGAAGAG-30 (257 bp); IGFBP3 gene, for-
ward 50-AAGTTGACTACGAGTCTCAG-30 and reverse 50-
AATCAGTTCACCACAAACAGA-30 (439 bp); IGFBP4
gene, forward 50-CACGAGGACCTCTACATCATC-30 and
reverse 50-CAGGACTCAGACTCAGACTC-30 (297 bp);
IGFBP5 gene, forward 50-GTCAAGATCGAGAGAGA-
CTC-30 and reverse 50-GAAGGTTTGCACTGCTTTCTC-30
(370 bp); IGFBP6 gene, forward 50-GTGTCCAAGACACT-
GAGATG-30 and reverse 50-CAACACCAACACTCTTTC-
CAAC-30 (404 bp); p27 gene, forward 50-GAGAAGCACT-
GCAGAGACAT-30 and reverse 50-AAGAATCGTCGGTTG-
CAGGT-30 (242 bp) and acidic riboprotein P0 (ARP0, also
known as 36B4) control gene, forward 50-AGATGCAGCA-
GATCCGCAT-30 and reverse 50-GTGGTGATACCTAAA-
GCCTG-30 (318 bp). The control gene ARP0 was checked
against a second control gene RPL13A and neither gene
was found to be affected by any of the treatments at the
time points used (data not shown). PCR product quality
was monitored using post-PCR melt curve analysis. Fold
inductions were calculated using the formula 2
 (DDCt),
where DDCt is the DCt(1a,25(OH)2D3)   DCt(Ethanol), DCt is
Ct(IGFBPn or p27)   Ct(ARP0) and Ct is the cycle at which the
threshold is crossed.
DNA constructs
Full-length cDNAs for human VDR (15) and human RXRa
(26) were subcloned into the T7/SV40 promoter-driven pSG5
expression vector (Stratagene, LaJolla, CA). The same con-
structs were used for both T7 RNA polymerase-driven in vitro
transcription/translation of the respective cDNAs and for viral
promoter-driven overexpression in mammalian cells. Each
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factor (ANF) (27) and the 15 candidate response elements
(REs) of the IGFBP genes (for sequence see Table 1) were
fused with the thymidine kinase promoter driving the ﬁreﬂy
luciferase reporter gene. All constructs were veriﬁed by
sequencing.
Transfection and luciferase reporter gene assays
MCF-7, PC-3 and SaOS-2 cells were seeded into 6-well plates
(10
5 cells/ml) and grown overnight in phenol red-free DMEM
supplemented with 5% charcoal-stripped FBS. Plasmid DNA
containing liposomes were formed by incubating a reporter
plasmid and the expression vector for human VDR (each 1 mg)
with 10 mg N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethyl-
ammonium methylsulfate (DOTAP, Roth, Karlsruhe,
Germany) for 15 min at room temperature in a total volume
of 100 ml. After dilution with 900 ml phenol red-free DMEM,
the liposomes were added to the cells. Phenol red-free DMEM
supplemented with 500 ml 15% charcoal-stripped FBS was
added 4 h after transfection. At this time, 100 nM 1a,
25(OH)2D3 or solvent were also added. The cells were
lysed 16 h after onset of stimulation using reporter gene
lysis buffer (Roche Diagnostics, Mannheim, Germany). The
constant light signal luciferase reporter gene assay was per-
formed as recommended by the supplier (Canberra-Packard,
Groningen, The Netherlands). Luciferase activities were nor-
malized with respect to protein concentration and induction
factors were calculated as the ratio of luciferase activity of
ligand-stimulated cells to that of solvent controls.
Gelshift assay
In vitro translated VDR and RXR proteins were generated by
coupled in vitro transcription/translation using their respective
pSG5-based full-length cDNA expression constructs and
rabbit reticulocyte lysate as recommended by the supplier
(Promega, Madison, WI). Protein batches were quantiﬁed
by test translation in the presence of [
35S]methionine. The
speciﬁc concentration of the receptor proteins was adjusted
to  4 ng/ml (10 ng corresponds to  0.2 pmol) after taking the
individual number of methionine residues per protein into
account. Gelshift assays were performed with 10 ng of the
appropriate in vitro translated proteins. The proteins were
incubated for 15 min in a total volume of 20 ml binding buffer
(150 mM KCl, 1 mM DTT, 0.2 mg/ml poly(dI-C), 5% glycerol
and10mMHEPES,pH7.9).Constantamounts(1ng)of[
32P]-
labeled double-stranded oligonucleotides (50000 c.p.m.)
containing one copy of the respective REs (Table 1) were
then added and incubation was continued for 20 min at
room temperature. Protein–DNA complexes were resolved
byelectrophoresisthrough8%non-denaturingpolyacrylamide
gels (mono- to bisacrylamide ratio 19:1) in 0.5x TBE (45 mM
Tris–HCl, 45 mM boric acid and 1 mM EDTA, pH 8.3) for 105
min at 200 V and quantiﬁed on a FLA-3000 reader (Fuji,
Tokyo, Japan) using ScienceLab99 software (Fuji).
ChIP assays
Nuclear proteins were crosslinked to genomic DNA by adding
formaldehyde for 15 min directly to the medium to a ﬁnal
concentration of 1%. Crosslinking was stopped by adding
glycine to a ﬁnal concentration of 0.125 M and incubating
for 5 min at room temperature on a rocking platform. The
medium was removed and the cells were washed twice with
ice-cold phosphate-buffered saline (PBS) (140 mM NaCl, 2.7
mM KCl, 1.5 mM KH2PO4 and 8.1 mM Na2HPO4 2H2O).
The cells were collected by scraping in ice-cold PBS supple-
mented with a protease inhibitor cocktail (Roche Diagnostics).
After centrifugation the cell pellets were resuspended in lysis
buffer(1%SDS,10mMEDTA,proteaseinhibitorsand50mM
Tris–HCl, pH 8.1) and the lysates were sonicated to result in
DNA fragments of 300–1000 bp in length. Cellular debris was
removed by centrifugation and the lysates were diluted 1:10 in
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM NaCl, protease inhibitors and 16.7 mM Tris–
HCl, pH 8.1). Non-speciﬁc background was removed by
incubating the chromatin resuspension with a salmon sperm
DNA/protein A agarose slurry (Upstate Biotechnology,
Table 1. Sequence and position of putative REs within the human IGFBP1, 2, 3 and 5 genes
RE Type Gene Position Strand Gene area Sequence
rANF DR3 rat ANF  907 + promoter agAGGTCAtgaAGGACA
RE1 DR3 IGFBP1  4533   promoter tcGGTTCTggaAGATCA
RE2 ER7 IGFBP1  3111 + promoter TGACCCctgccagGGGGCA
RE3 DR3 IGFBP1/3 +5327 + intergenic ctGGGGCAggcGGGGCA
RE4 ER7 IGFBP1/3 +15359 + intergenic TGAACTtggagatAGGTCA
RE5 ER7 IGFBP1/3 +18886 + intergenic TGAACTccacagaAGTTCA
RE6 DR3 IGFBP3  387   promoter cgGGGTCAaggAGATCG
RE7 DR3 IGFBP3  396   promoter taAGGGCGgcgGGGTCA
RE8 DR3 IGFBP3  3347 + promoter gaGGTTCAccgGGTGCA
RE9 DR3 IGFBP2 +17676 + 1st intron aaAGGTCAgagGGGGCA
RE10 DR4 IGFBP2 +24655   1st intron agGGTTCAttgaGGGGCA
RE11 DR3 IGFBP2/5 +35665   intergenic ctGGTTCAttcAGATCA
RE12 DR3 IGFBP2/5 +37171 + intergenic gtGGGTTAtatGGGTCG
RE13 ER9 IGFBP5 +7775 + 1st intron TGACCCatcacagccAGTTCA
RE13+ ER11 IGFBP5 +7775 + 1st intron TGACCCacatcacagccAGTTCA
RE14 DR4 IGFBP5  4679 + promoter atAGGGCAgagcAGGGCA
RE15 ER8 IGFBP5  7384 + promoter TGAACCgaaagctgGGTTCA
The known DR3-type VDRE of the rat ANF gene (28) serves as a comparison. Capital letters indicate hexameric core binding sites. The position of the RE is given
relative to the TSS of the indicated gene.
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ples were centrifuged and the recovered chromatin solutions
were incubated with 5 ml of indicated antibodies overnight at
4 C with rotation. The antibodies against VDR (sc-1008),
RXRa (sc-553), SMRT (sc-1610), SRC-1 (sc-7216),
TRAP220 (sc-5334), P-Pol II (sc-13583), IgG (sc-2027) and
p53 (sc-6243) were obtained from Santa Cruz Biotechnologies
(Heidelberg, Germany). The immuno-complexes were collec-
ted with 60 ml of protein A agarose slurry (Upstate Biotech-
nology) for 2 h at 4 C with rotation. The beads were pelleted
by centrifugation for 1 min at 4 C at 100· g and washed
sequentially for 5 min by rotation with 1 ml of the following
buffers: low salt wash buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 150 mM NaCl and 20 mM Tris–HCl, pH 8.1),
high salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 500 mM NaCl and 20 mM Tris–HCl, pH 8.1) and LiCl
wash buffer (0.25 mM LiCl, 1% Nonidet P-40, 1% sodium
deoxycholate, 1 mM EDTA and 10 mM Tris–HCl, pH 8.1).
Finally, the beads were washed twice with 1 ml TE buffer
(1 mM EDTA and 10 mM Tris–HCl, pH 8.0). The immuno-
complexes were then eluted by adding 250 ml elution buffer
(1% SDS and 100 mM NaHCO3) and incubation for 15 min at
room temperature with rotation. After centrifugation, the
supernatant was collected and the elution was repeated. The
supernatants were combined and the cross-linking was
reversed by adding NaCl to ﬁnal concentration of 200 mM
and incubating overnight at 65 C. The remaining proteins
were digested by adding proteinase K (ﬁnal concentration
40 mg/ml) and incubation for 1 h at 45 C. Genomic DNA
fragments were recovered using the Qiaex II Gel Extraction
Kit (Qiagen, Hilden, Germany).
PCR of chromatin templates
For each of the 14 candidate RE-containing genomic regions
and the TSS of the genes IGFBP1, 2, 3 and 5 primer pairs were
designed (Table 2), optimized and controlled by running PCRs
with 25 ng genomic DNA (input) as a template. When running
immuno-precipitated DNA (output) as a template, following
PCR proﬁle was used: preincubation for 5 min at 94 C,
40 cycles of 30 s at 95 C, 30 s at 60 C and 30 s at 72 C
and one ﬁnal incubation for 10 min at 72 C. The PCR products
were separated by electrophoresis through 2.0% agarose. Dye
SybrGreen (1 ml) (1:2500 dilution) was added to each sample
before loading. Gel images were scanned on a Fuji FLA3000
reader using ScienceLab99 software.
RESULTS
Basal expression of IGFBP gene family members in
prostate and bone cancer
The basal mRNA expression levels of all six members of the
IGFBP gene family were monitored by real-time quantitative
PCR in relation to the control gene ARP0 in PC-3 human
prostate cancer (Figure 1A) and SaOS-2 human osteosarcoma
cells (Figure 1B). In both cell lines the genes IGFBP4 and
6 showed the highest expression, but in SaOS-2 cells these
maximal levels were  10-fold lower than in PC-3 cells. In PC-
3 cells the mRNA amount of IGFBP1 and 3 was  15-fold
lower, that of IGFBP-2 >300-fold lower and that of IGFBP5
even 12000-foldlowerthanthatofIGFBP4and6(Figure1A).
In contrast, in SaOS-2 cells the differences in the expression of
the IGFBP gene family members showed less pronouced dif-
ferences, since the mRNA levels of IGFBP3 and 5 were only
 3-fold lower and that of IGFBP1 and 2 only 30-fold lower
than that of IGFBP4 and 6 (Figure 1B).
IGFBP1,3and5areprimary1a,25(OH)2D3targetgenes
PC-3 and SaOS-2 cells were treated for 24 h with 10 nM
1a,25(OH)2D3 in the absence or presence of the protein trans-
lation inhibitor cycloheximide in order to differentiate
between primary and secondary effects of the VDR ligand.
The relative fold induction of the mRNA amounts of the six
IGFBP genes and of the known secondary 1a,25(OH)2D3
target gene p27 (9) were determinded by real-time quantitative
PCR (Figure 1C and D). In PC-3 cells the genes IGFBP1, 3
and 5 were found to be 2- to 4-fold induced by 1a,25(OH)2D3
and this induction was not signiﬁcantly modulated by the
presence of cycloheximide (Figure 1C). The three other
IGFBP gene family members and the p27 gene showed in
this cell line no response to the natural VDR ligand. In
SaOS-2 cells the genes IGFBP1, 3 and 5 were also 2- to
Table 2. Genomic PCR primers
Region (gene) Location Primer sequences (50–30)
1 (IGFBP1)  4371 to
 4156
CTCTACATCTTTGAGGGTGGG
GACGTGGGAGAATCGTTTGAG
2 (IGFBP1)  3246 to
 3062
CTGCACTTCCCAGAGCTGAG
GTTACAGCCGATGATGTGAC
3 (IGFBP1/3) +5077 to
+5415
CTGTGGTGATGTTGCCACCTG
GAGGATGGGGACTAATGGAGAG
4 (IGFBP1/3) +15255 to
+15576
GAGAACTAAATGGAAATGCTGGAG
CTGGAATAAATCCCACTGATCATG
5 (IGFBP1/3) +18796 to
+19008
CTTACTAGGCAGCGTTCTCATG
CTGTCTACCAGCGACAACCAAC
6/7 (IGFBP3)  280 to
 483
GTCACCTTGTCGTCTACAAG
CACGAGGTACACACGAATGC
8 (IGFBP3)  3286 to
 3465
CTGGAGTGACTCACCAGAGTC
CTTGCCTGCCTCTCTCAGCTG
9 (IGFBP2) +17599 to
+17734
GAATGTGTCCTGAGTGCCAG
GTCCTGAGACTTTGTGGGTG
10 (IGFBP2) +18965 to
+19136
GTTACTCCATGTTGGTCAGACTG
GAGATTCACTCACGAGTCAGAAC
11 (IGFBP2/5) +35559 to
+35740
CATGAACTGCAACTGTGATGTC
CAATAAGCCACCAGGTGCTAG
12 (IGFBP2/5) +37095 to
+37295
GAGACAGGAGTGGAGTAGTC
CACACTGCCTGGAGCAGGTG
13 (IGFBP5) +7887 to
+7635
CTGTCTGTTCCTCATACATTC
CTCCCTTGTTTGGTCCCTAG
14 (IGFBP5)  4572 to
 4740
GAGCCAGCTGTGACGCAGAG
GAACATGCCAGATCCCATGATC
15 (IGFBP5)  7275 to
 7535
GATGGCTCTGTACTCAAGGAG
CTCAGAGGATAAGTCCTGAGTC
IGFBP1 TSS  100 to
+153
GAACACTCAGCTCCTAGCGTG
CTGACATCTCCAGGCGCGAG
IGFBP3 TSS  129 to
+92
GAGCAGCACCAGCAGAGTC
CAGGGATGGGGCGACAGTAC
IGFBP2 TSS  62 to
+117
GAAGGGAGTGGTCTCCAAAAG
CACTCTCGGCAGCATGCTG
IGFBP5 TSS  32 to
+92
GTTCTACGCGAAGTCCGGAG
CTCCTTGGCATCCTTGCCTG
Sequence and location of the primer pairs used to detect genomic regions
containing putative VDREs or TSS within the IGFBP1 and 3 and IGFBP2
and 5 gene pairs. The location is indicated in relation to the closest TSS.
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Figure 1. ExpressionprofilingofthehumanIGFBPgenefamilyinprostateandbonecancercells.Real-timequantitativePCRwasusedtodeterminetheratioofthe
basalmRNAexpressionofthesixIGFBPgenesrelativetothecontrolgeneARP0inPC-3(A)andSaOS-2cells(B).AlogarithmicscaleisemployedontheY-axisto
betterpresentthedata.Inthesamecelllines,theinductionofmRNAlevelsofthesixIGFBPgenesandoftheknownsecondary1a,25(OH)2D3targetgenep27aftera
24 h treatment with 10 nM 1a,25(OH)2D3 was determined in the absence and presense of 10 mM cycloheximde (C and D). The early time course (2 to 6 h) of the
mRNAexpressionofallsevengenesinresponseto10nM1a,25(OH)2D3wasalsomeasuredinPC-3(E)andSaOS-2(F)cells.Datapoints(AandB)andcolumns(C–
F)indicatethemeansofatleastthreeindependentcelltreatmentsandthebarsrepresentstandarddeviations.Thestandarddeviationsin(AandB)aretoosmalltobe
visibleinrelationtothedatapoints.Two-tailedStudent’st-testswereperformedtodeterminethesignificanceofthemRNAinductionby1a,25(OH)2D3inreference
to solvent controls (*P < 0.05, **P < 0.01, ***P < 0.001).
Nucleic Acids Research, 2005, Vol. 33, No. 17 55254-fold inducible by 1a,25(OH)2D3 without being signiﬁcantly
affected by cycloheximide (Figure 1D). Interestingly, in this
cell line even the genes IGFBP4, IGFBP6 and p27 responded
1.5- to 2.2-fold to 1a,25(OH)2D3 treatment, but this induction
disappeared in the presence of cycloheximide. This observa-
tion indicates that the IGFBP4 and 6 gene are only secondary
1a,25(OH)2D3 targets as is known for the p27 gene. The
IGFBP2 gene did not respond at all to ligand treatment.
Next, we performed in both cell lines a time course analysis
of the early mRNA expression of all six IGFBP genes and the
p27 gene in response to 1a,25(OH)2D3 over 2, 4 and 6 h
(Figure 1E and F). In conﬁrmation of the results obtained
in Figure 1C and D, only the IGFBP1, 3 and 5 gene, but
neither the genes IGFBP2, 4 and 6 nor the p27 gene responded
within this time frame to the natural VDR ligand. After 4 and
6 h of ligand treatment the response of the IGFBP3 gene
showed a stable 2.5- and 4-fold induction in PC-3 and
SaOS-2 cells, respectively. In contrast, the expression of the
genes IGFBP1 and 5 demonstrated a more cell-speciﬁc proﬁle
(compare Figure 1E and F). In PC-3 cells IGFBP1 mRNA was
induced 3-fold after 6 h of stimulation with 1a,25(OH)2D3,
while in SaOS-2 cells it showed a comparable peak already
after 4 h. Moreover, in PC-3 cells IGFBP5 mRNA expression
was after 4 and 6 h constantly 3-fold increased, while in SaOS-
2cellsitdisplayedasmaller peakofonly2-foldinductionafter
4 h stimulation with ligand. Taken together, in both cell lines
the genes IGFBP1, 3 and 5 but not IGFBP2, 4 and 6 are
primary 1a,25(OH)2D3 target genes.
In silico screening for putative VDREs
Based on a list of >15 known natural VDREs (28) we obtained
the consensus hexameric core sequence RGDKYR (R ¼ Go r
A, D ¼ A,G or T, K ¼ Go rT ,Y¼ C or T) and used it to
screen in silico the gene area (deﬁned as 10 kb upstream of the
TSS until the end of the last exon) of each of the six human
IGFBP genes for putative VDREs. Since the genes IGFBP1
and 3aswell as IGFBP2and 5are foundadjacentto each other
in the genome (Figure 2), we also screened the intergenic area
between these two gene pairs. For the speciﬁc search for
VDREs we considered only hexameric core sequence pairs
in DR3, DR4, ER6, ER7, ER8 or ER9 orientation. Moreover,
we kept onlyRE candidatesformed ofhexamers with maximal
two deviations from the optimal RGKTCA core binding
sequence in our list and excluded putative VDREs being
located in Alu repetitive sequence (representing  12% of
the 174 kb genomic sequence screened in total). These restric-
tions ﬁnally resulted in 15 putative VDREs, of which two (REs
1 and 2) were located in the area of the IGFBP1 gene, three
(REs 3, 4 and 5) between the genes IGFBP1 and 3, three (REs
6, 7 and 8) in the IGFBP3 gene, two (REs 9 and 10) in the
IGFBP2 gene, two (REs 11 and 12) between the genes
IGFBP2 and 5 and three (REs 13, 14 and 15) in the
IGFBP5 gene (Figure 2). In contrast, no REs were found in
the genes IGFBP4 and 6.
Themajority(eight)oftheREs areofDR3-type.Therewere
also two DR4-type, three ER7-type, one ER8-type and one
ER9-type REs (Table 1). The DR3-type RE8 in the promoter
of the IGFBP3 gene has already been described as a functional
VDRE (10), whereas the 14 remaining putative VDREs are
novel. Interestingly, REs 6 and 7 form a composite RE of three
hexameric binding motifs. Moreover, all REs were screened in
the database dbSNP (www.ncbi.nlm.nih.gov/SNP) for known
small nucleotide polymorphisms (SNPs) and for RE13 a 2 nt
insertion variation was found (RE13+ in Table 1), which was
included in the following RE evaluation. In summary, in silico
screening resulted in15 putative VDREs inthe genes IGFBP1,
2, 3 and 5, but none in the genes IGFBP4 and 6. This result is
mostly in agreement with the observation that the genes
IGFBP1, 3 and 5 but not IGFBP2, 4 and 6 are primary
1a,25(OH)2D3 targets.
Functionality of putative VDREs within the
IGFBP genes
Thefunctionalityofthe 15putativeVDREsidentiﬁedinsilico,
the SNP variation of RE13 (RE13+) and the reference DR3-
type VDRE of the rat ANF gene (27) was assessed by reporter
gene assays in transiently transfected MCF-7 breast cancer
cells (Figure 3A), PC-3 cells (Figure 3B) and SaOS-2 cells
(Figure 3C). MCF-7 cells represent an established
1a,25(OH)2D3 responding cell line (19) and were chosen as
reference to other studies. Two copies of each of the 15 putat-
ive VDREs, RE13+ and the rat ANF VDRE were fused with
the thymidine kinase promoter driving the ﬁreﬂy luciferase
reporter gene. The response to 1a,25(OH)2D3 of the three
different cell lines transfected with these constructs was mon-
itored after 16 h. As expected, MCF-7 cells showed the highest
inducibilty by 1a,25(OH)2D3: compared with the 16.9-fold
inducibility of the reference VDRE, REs 8, 2 and 13 were
IGFBP2 IGFBP5
IGFBP1
IGFBP4
IGFBP6
IGFBP3
5 kb
exon
TSS
predicted binding site
RE1 RE2 RE4 RE5 RE3 RE6/7 RE8
RE9 RE10 RE11 RE12 RE13 RE14 RE15
chromosome 7 from nucleotide 
45,691,327 to 45,744,052
chromosome 2 from nucleotide 
217,313,633 to 217,395,777
chromosome 17 from nucleotide 
35,843,236 to 35,867,457
chromosome 12 from nucleotide 
51,767,716 to 51,782,391
Figure 2. Overviewon thegenomicorganizationandlocationofthe sixhumanIGFBPfamilymembers.HumangenomicDNA (174kb)(thinblackline)from four
differentchromosomescomprisingallsixhumanIGFBPgeneswerescreenedinsilicoforputativeVDREs.FifteencandidateREs(redboxes)wereidentifiedinthe
genes IGFBP1, 2, 3 and 5 but none in IGFBP4 and 6. The sequences of the REs are indicated in Table 1.
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Figure 3. FunctionalityofputativeVDREsderivedfromhumanIGFBPgenes.ReportergeneassayswereperformedwithextractsfromMCF-7cells(A),PC-3cells
(B) and SaOS-2 cells (C) that were transiently transfected with luciferase reporter constructs each containing two copies of one of the 15 candidate VDREs and the
SNPvariationofRE13(RE13+)oroftheratANFDR3-typeVDREandanexpressionvectorforhumanVDR.Cellsweretreatedfor16hwitheithersolventor100nM
1a,25(OH)2D3.Relativeluciferaseactivityisshownandfoldinductionsareindicatedabovethecolumns.Columnsrepresentmeansofatleastthreeexperimentsand
bars indicate SDs. Two-tailed Student’s t-tests were performed to determine the significance of reporter gene induction by 1a,25(OH)2D3 in reference to solvent
controls (*P < 0.05, **P < 0.01, ***P < 0.001).
Nucleic Acids Research, 2005, Vol. 33, No. 17 5527even more potentwith a51.4-, 28.5-and 22.4-foldinductionof
reporter gene activity (Figure 3A). The 13.2-, 9.9-, 9.5-, 6.9-,
5.0- and 4.9-fold induction mediated by two copies of the REs
5, 9, 4, 3, 10 and 14, respectively, indicate that they are able to
function as VDREs. In contrast, the SNP variation RE13+ lost
signiﬁcantly its 1a,25(OH)2D3 responsiveness and therefore
represents a less efﬁcient VDRE. Moreover, neither the abso-
lute reporter gene activity nor the inducibility of REs 1, 6, 7,
11, 12 and 15 was sufﬁcient for a functional VDRE.
The inducibility of PC-3 (Figure 3B) and SaOS-2 cells
(Figure 3C) were in average 5- and 10-fold lower than that
of MCF-7 cells, but concerning relative inducibility all three
cell lines provided similar results. RE8 was in all cells more
inducible than the reference VDRE, RE13 showed a compar-
able inducibility thanthe referenceVDRE andalso REs2, 4,5,
9 and 14 demonstrated a statistically signiﬁcant inducibility by
1a,25(OH)2D3 in all tested cell lines. However, owing to cell-
speciﬁc variations in the basal activity of the reporter gene
constructs carrying the different REs, the absolute activities of
the REs do not match perfectly between the three different
cell lines.
In vitro characterization of putative VDREs within
the IGFBP genes
To assess the relative VDR–RXR heterodimer binding, gel-
shift assays were performed using in vitro translated VDR and
RXR proteins either alone or in combination and the 15 putat-
ive VDREs of the IGFBP genes (Figure 4). The conditions
were identical to our earlier DR3-type VDRE comparative
study (28) and the DR3-type VDRE of the rat ANF gene
was chosen again as reference. The ER7-type REs 2 and 5
bound3.5-fold moreeffectively VDR–RXRheterodimersthan
the reference DR3-type VDRE and also the ER9-type RE13
and the ER7-type RE4 were 1.5- and 1.2-fold stronger,
respectively. Moreover, the DR3-type REs 9, 8 and 11 showed
with132, 110and75%ofthe bindingofthe reference REgood
afﬁnity for VDR–RXR heterodimers. Finally, the ER8-type
RE15 (67% heterodimer binding capacity) and the DR4-type
RE10 (44%) can be considered as VDREs as well. Interest-
ingly, the ER11-type SNP variation of RE13 (RE13+) still
showed 67% binding capacity of the reference VDRE
(which equals 44% of RE13). In contrast, the binding of
VDR–RXR heterodimers to the REs 1, 3, 6, 7, 12 and 14
was too low in our stringent assay conditions to consider
them as efﬁcient VDREs. Taken together, according to stand-
ardized in vitro criteria developed in our previous studies (28),
7 (REs 4, 8, 9, 10, 11, 13 and 15) of the 15 candidate REs show
0.5- to 1.5-fold of DNA-binding capacity of the reference
VDRE and can be considered as good VDREs. In addition,
two REs (REs 2 and 5) even demonstrated a 3.5-fold higher
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Figure 4. In vitro analysis of the putative VDREs derived from the human
IGFBP gene areas. Gelshift experiments were performed with in vitro trans-
latedhumanVDRandhumanRXRaloneorincombinationandinthepresence
of different [
32P]-labeled REs representing the 15 candidate VDREs and the
SNP variation of RE13 (RE13+) of the human IGFBP genes and the rat ANF
DR3-type reference VDRE. Protein–DNA complexes were resolved from free
probethroughnon-denaturing8%polyacrylamidegels.Representativegelsare
shown.TherelativeamountofVDR–RXRheterodimercomplexformationwas
quantified on a FLA-3000 reader in relation to the reference VDRE. Numbers
below the gels indicate the means of at least three independent gel shift experi-
mentsandtheirSDsaregiveninbrackets.NSindicatesnon-specificcomplexes.
5528 Nucleic Acids Research, 2005, Vol. 33, No. 17DNA-binding afﬁnity than the reference VDRE and should be
considered as high afﬁnity VDREs.
Overall there is good correlation between the reporter gene
assay results (Figure 3) and the in vitro analysis (Figure 4).
REs 2and 13 are conﬁrmed as very good VDREs and REs 1, 6,
7 and 12 showed no response in either of the two assays. The
response of RE8 in the functional assay was higher and that of
RE5 lower than expected, but both REs appeared to be very
effective VDREs. Finally, REs 4 and 9 were also conﬁrmed as
VDREs. In summary, a number of VDREs (REs 2, 4, 5, 8, 9
and 13) were shown to respond effectively to 1a,25(OH)2D3
and its receptor in both evaluation series.
Functionality of putative VDREs in chromatin
context of living cells
We next examined whether VDR was located to the genomic
regions containing these REs in living cells. Chromatin was
extracted from PC-3 cells which had been grown overnight in
the presence of 5% charcoal-treated FBS, stimulated for 0, 0.5,
1, 2, 3 and 4 h with 10 nM 1a,25(OH)2D3 and then crosslinked
for 15 min in the presence of formaldehyde. ChIP assays were
performed using an antibody against VDR. The genomic DNA
fragments that were recovered from reverse-crosslinked chro-
matin served as templates for PCRs with primers speciﬁc for
the regions containing the 15 putative VDREs (Table 2). Since
REs 6 and 7 are in the same region, they cannot be detected
separately and therefore represented together. Representative
agarose gels of the PCR products from all treatment times are
shown (Figure 5A). The input lane serves as a reference for
comparable detection sensitivity for the 14 genomic regions
within the IGFBP1 and 3 and IGFBP2 and 5 gene tandems
(Figure 2) and ChIP assays using IgG or anti-p53 antibody
served as controls. Interestingly, with the exception of regions
11, 12 and 15, on the remaining 11 genomic regions VDR
binding could be detected (Figure 5A). On some of the latter
regions, such as regions 2, 3, 6/7, 8, 9, 10, 13 and 14, VDR
binding was found in the absence of ligand. Moreover,
1a,25(OH)2D3 treatment did not signiﬁcantly affect the bind-
ing of its receptor to these genomic regions, but on some
regions (2, 8, 9 and 10) the tendency of a maximal binding
after 2 h could be observed. Only on regions 1, 4 and 5 a sig-
niﬁcant 1a,25(OH)2D3-dependent modulation of the VDR
association could be detected.
For a deeper analysis of the 11 VDR-associated regions of
the IGFBP1/3 and 2/5 gene cluster, further ChIP assays were
performed with antibodies against RXR, the corepressor
SMRT, the coactivator SRC-1, the mediator protein
TRAP220 and P-Pol II (Figure 5B). With the exception of
region 1, on the remaining 10 genomic regions RXR
Figure 5. Association of RE-containing genomic regions and proximal promoters of IFGBP genes with VDR and other nuclear proteins. Chromatin was extracted
from PC-3 cells that had been treated for indicated time periods with 10 nM 1a,25(OH)2D3. ChIP experiments were performed with anti-VDR, anti-RXR, anti-
SMRT,anti-SRC-1,anti-TRAP220oranti-P-PolIIantibodies.Anti-IgGandanti-p53antibodieswereusedasnon-specificcontrols.Thesedisplaysomebackground
signal for the regions9, 10 and 14. The association of VDR and its partner proteins was monitored on the 14 RE-containinggenomic regions (A and B) of the genes
IGFBP1, 2, 3 and 5 and their proximal promoters (C). Representative agarose gels are shown.
Nucleic Acids Research, 2005, Vol. 33, No. 17 5529association was found.ThisRXRbindingwas notsigniﬁcantly
modulated by 1a,25(OH)2D3 treatment in most cases. In the
latter aspect, the binding of SMRT to the 10 VDR- and RXR-
positive genomic regions provided a clearer picture. In the
absence of ligand SMRT binding was detected on all 10
regions containing a putative VDRE with the exception of
regions 9 and 10. This SMRT binding was diminished after
30–120 min of 1a,25(OH)2D3 treatment. Interestingly, on
some of these eight regions (regions 4, 5 13 and 14) SMRT
binding was reconstituted after 1 to 3 h of ligand application,
while for regions 2, 3, 6/7 and 8 the measurement window of
4 h was apparently too short to observe the return of the
corepressor. This indicates that for each region an idiosyn-
cratic corepressor association proﬁle exists. A similar indi-
vidual proﬁle is observed concerning the binding of SRC-1
to the 10 genomic regions. On none of the regions SRC-1 was
observed to bind in the absence of ligand and it took 30–
240 min of 1a,25(OH)2D3 treatment to observe coactivator
association. Moreover, the duration of the SRC-1 association
varied between  1 h for the genomic regions 2, 4, 13 and 14 to
>3 h for regions 9 and 10. The association of the mediator
TRAP220 and P-Pol II with the 10 genomic regions appeared
to be timely coordinated and showed for most regions a peak
of  1 h duration after 1–2 h of ligand treatment. Taken
together, the IGFBP1/3 and 2/5 gene cluster contain 10
VDR- and RXR-associated regions (2, 3, 4, 5, 6/7, 8, 9, 10,
13 and 14), which each shows an individual, ligand-dependent
proﬁle of SMRT, SRC-1, TRAP220 and P-Pol II binding.
The IGFBP2 gene is not transcriptionally regulated
by 1a,25(OH)2D3
The REs 9 and 10 are located within the large ﬁrst intron of the
IGFBP2 genebutare already >17and24 kbdownstream ofthe
TSS (Figure 2). This raised the question, whether they are
involved in the regulation of the IGFBP2 gene or whether
they may regulate the IGFBP5 gene, although the TSS of
the latter gene is even more distant. We tried to answer this
question indirectly by assessing via ChIP assays a 1a,
25(OH)2D3-dependent association of VDR with the TSS of
the genes IGFBP1, 2, 3 and 5 (Figure 5C). From this it was
found that VDR interacts with the proximal promoter of the
genes IGFBP1, 3 and 5 but not to that of IGFBP2. The VDR
interaction with the TSS of the IGFBP1 gene was clearly
ligand-dependent with a peak after 1 h stimulation, whereas
that on the IGFBP3 and 5 gene TSS was only weakly modu-
lated by 1a,25(OH)2D3. These ﬁndings conﬁrm the real-time
quantitative PCR results (Figure 1) that the genes IGFBP1, 3
and 5 but not the IGFBP2 gene are regulated by VDR and its
ligand. This observation also suggests that the association of
VDR to REs 9 and 10 is not related to a regulation of the gene,
IGFBP2, in which they are located.
DISCUSSION
This study describes the regulation of multiple IFGBP gene
family members by the hormone 1a,25(OH)2D3. We con-
ﬁrmed a previous study (10) that IGFBP3 is a primary
VDR target gene and found in addition that its direct genome
neighbor, the IGFBP1 gene, is also a primary target of
1a,25(OH)2D3. Moreover, we even could identify a third fam-
ily member, the IGFBP5 gene, as a primary VDR target,
whereas the mRNA expression of its tandem partner, the
IGFBP2 gene, was not regulated by the nuclear receptor
and its ligand. We observed these primary ligand responses
in prostate and bone cancer cells, but it can be assumed that
these three genes may also be VDR targets in other
1a,25(OH)2D3 responsive tissues. The 2- to 4-fold induction
of IGFBP1, 3 and 5 is not a very strong up-regulation, but it is
in the order of what was observed with most other 1a,
25(OH)2D3 target genes (29,30). The genes IGFBP4 and 6
showed in both tested cell lines the highest basal expression of
the six IGFBP genes, so that a further up-regulation of their
expression through 1a,25(OH)2D3 may not be necessary.
However, in SaOS-2 cells, which show a signiﬁcantly lower
IGFBP4 and 6 mRNA expression than PC-3 cells, both genes
were shown to be secondary 1a,25(OH)2D3 targets.
Our ﬁnding that three members of the IFGBP gene family
respond to 1a,25(OH)2D3 increases the impact of IGF-1 and
the regulation of its circulating amounts by IGFBPs in models
of the anti-proliferative action of 1a,25(OH)2D3 and its
synthetic analogs (31). In addition, IGFBPs mediate IGF-
independent actions, including the activation of the p21
gene, causing cell cycle arrest or cell death through induction
of apoptosis (32). However bound to cellular membranes,
IGFBPs can have mitogenic, IGF-dependent effects on cellu-
lar growth (33,34). For example, the effect of IGFBP5 induc-
tion has been described mitogenic, when induced by
androgens in prostate cells (35). This complicates the inter-
pretation of the up-regulation of the IGFBP family members
by 1a,25(OH)2D3. The differential regulation of several other
primary and secondary 1a,25(OH)2D3 target genes, such as
the down-regulation of IGF-1 and the up-regulation of the p21
gene, has to be considered in context of the response of IFG-
BPs. Since the mitogenic effect of IGFBPs is IGF-dependent,
1a,25(OH)2D3 seems to promote the IGF-independent path-
way of IGFBPs.
The in silico screening performed in this study involved
a deﬁned six-member gene family and 174 kb genomic
sequence. After a number of carefully selected restrictions
the screen resulted in 15 candidate VDREs. ChIP assays indic-
ated that 10 of these 15 REs are bound by VDR in intact PC-3
cells. This represents a 67% success rate of the in silico pre-
diction of VDR binding sites, which is much higher than
in comparable screenings (36). Moreover, non-ligand respons-
ive genes, such as IGFBP4 and 6, did not contain any VDRE
candidates, although 24 and 15 kb, respectively, of their
genomic sequence were screened. The other non-ligand
responsive gene, IGFBP2, contains two VDREs (REs 9 and
10) within its ﬁrst intron. However, ChIP analysis of the prox-
imal promoter region of the IGFBP2 gene indicated that these
VDREs cannot be in contact with the TSS of this gene. It is
therefore more probable that they are involved in the regula-
tion of the neighboring IGFBP5 gene. The high success rate
of our combined in silico screen/ChIP analysis method sug-
gests that its application on even larger screenings involving
megabases of genomic sequence is possible.
It is important to note that our in silico screening was not
restricted to regulatory regions that comprise only maximal 2
kb of sequence upstream and downstream of the TSS, as in
a recent whole genome screen for regulatory elements (37),
but involved up to 10 kb upstream sequence, intronic and even
intergenic sequences. Therefore, our method reveals candidate
5530 Nucleic Acids Research, 2005, Vol. 33, No. 17REs that are located at >30 kb distannce from the TSS that is
regulated by this VDRE. Based on the present understanding
of enhancers, DNA looping and chromatin units being ﬂanked
by insulators or matrix attachment sites (38) these distances
are no limitations. However, such large distances between RE
and TSS cannot be assessed by older experimental approaches,
such as transiently transfected promoter reporter gene fusion
constructs and the validation of critical promoter regions via
truncations or point mutations. In contrast, ChIP assays omit
the need of transient transfections and allow the analysis of
every region in a genome in vivo or in situ.
The observation that the IGFBP1/3 gene cluster contains six
functional VDR associated regions (2, 3, 4, 5, 6/7 and 8) and
the IGFBP5 gene area four such regions (9, 10, 13 and 14)
supports the model of multiple VDREs per primary 1a,
25(OH)2D3 target gene, which we developed during our ana-
lysis of the CYP24 and cyclin C gene (18,19). Interestingly, the
VDR-associated genomic regions contain three ER7-type
(REs 2, 4 and 5) and one ER9-type (RE 13) VDREs. All
four REs showed to bind VDR–RXR heterodimers strongly
in vitro and are potent VDREs in reporter gene assays.
Although synthetic ER7-type VDREs have been known
since more than a decade (16), this study demonstrates for
the ﬁrst time the existence of functional ER7-type VDREs in
vivo. Similarly, the ER9-type RE13 is one of the ﬁrst natural
VDREs of this type. Interestingly, the SNP variation that
increases the spacing of this VDRE by 2 nt, forming the
ER11-type RE13+, signiﬁcantly decreases its ability to func-
tion as a VDRE in vitro and in reporter gene assays. Unfor-
tunately,theSNPvariationoccursonlywith afrequencyof3%
in the population, so that we presently have no cellular system
testing its effect in ChIP assays.
In conclusion, our study has provided insight into the
regulation of the IGFBP gene family by 1a,25(OH)2D3.
We demonstrated that IGFBP1, 3 and 5 are primary 1a,
25(OH)2D3 target genes. Each of these three genes contains
multiple functional VDR associated regions in their genomic
area suggesting a complex regulation by 1a,25(OH)2D3.
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